Outcomes4Me, the developer of the leading direct-to-patient, AI-driven platform transforming the cancer care experience, announced the close of a $21M funding round.
“AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale,” said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me. “With more than 280,000 cancer patients using our AI-enabled platform, we’re not just offering people diagnosed with cancer a tool, we’re empowering them with intelligent, real-time insights that guide them through every step of their care. This funding will help us further enhance our platform, expand our reach, and drive meaningful revenue growth.”
With this round, Outcomes4Me welcomes new investor London-based Salica Investments, with participation from all existing investors: Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD, bringing Outcomes4Me’s total capital raised to date to $38M.
Also Read: Roundtrip and ESO Solutions Integrate to Streamline Non-Emergency Medical Transportation with Automated Ride Planning
AI at the Core of Cancer Care
The future of cancer care is digital, data-driven, and deeply personalized. Outcomes4Me’s AI-driven platform integrates real-time clinical guidelines, genomic insights, medication and symptom tracking, clinical trial matching, and patient peer communities into a single, easy-to-use interface for patients with cancer. By combining cutting-edge AI with deep oncology expertise and generating new multimodal patient-level data enriched at the drug level, Outcomes4Me is uniquely positioned to accelerate the pace of innovation in cancer care, driving both improved patient outcomes and sustainable revenue growth.
“Outcomes4Me is an AI-driven pioneer in the oncology space, scaling rapidly in a market that demands smarter, personalized healthcare solutions,” said Amy Summy, Executive Vice President, Chief Marketing Officer and Consumer Lead for Labcorp. “We are excited to support their digital platform as part of our deep commitment to help advance oncology care and improve patient outcomes.”
SOURCE: PRNewswire